QNRX Insider Trading Activity and SEC Form 4 Filings
QNRX insider trading summary
Over the past 12 months, insiders at Quoin Pharmaceuticals, Ltd. (QNRX) reported 4 open-market purchases worth $280K by 4 insiders and no sales on SEC Form 4. Net insider buying was $280K.
Latest QNRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Denise P. Carter | Chief Operating Officer | Buy | $100K (20,490 @ $4.88) |
| Aug 31, 2026 | Michael Myers | Chief Executive Officer | Buy | $100K (20,490 @ $4.88) |
| Aug 31, 2026 | Sally Bridget Lawlor | Chief Financial Officer | Buy | $50K (10,244 @ $4.88) |
| Aug 31, 2026 | Anthony James Culverwell | Director | Buy | $30K (6,146 @ $4.88) |
| Oct 14, 2025 | Dennis Langer | Director | Buy | $129K (15,152 @ $8.49) |
| Dec 23, 2024 | Michael Myers | Chief Executive Officer | Buy | $250K (555,556 @ $0.45) |
| Dec 23, 2024 | Gordon Dunn | Chief Financial Officer | Buy | $55K (122,221 @ $0.45) |
| Dec 23, 2024 | Anthony James Culverwell | Director | Buy | $45K (100,000 @ $0.45) |
| Dec 23, 2024 | Denise P. Carter | Chief Operating Officer | Buy | $250K (555,556 @ $0.45) |
| Sep 10, 2024 | Gordon Dunn | Chief Financial Officer | Buy | $9K (10,000 @ $0.91) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.